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3Take Home Message
In a randomized setting, intermediate- or high-risk prostate cancer patients treated with
adjuvant chemotherapy with docetaxel following radical radiotherapy and ADT did not show
improved biochemical disease-free survival compared to those who underwent radical
radiotherapy and ADT alone. More adverse events occurred with the combined treatment, but
there were less PSA relapses than were estimated to occur in both groups.
4Background: Docetaxel combined with androgen deprivation therapy (ADT) has improved
patient survival for advanced prostate cancer (PCa).
Objective: This randomized trial evaluated if six courses of docetaxel improved the
biochemical disease-free survival (BDFS) after radical radiotherapy (RT) for intermediate- or
high-risk PCa patients.
Design, setting and participants: A total of 376 patients were randomized in this multinational
phase III study and received either 6 cycles of adjuvant docetaxel 75 mg/m2 every 3 weeks
without continuous prednisone (Arm A, n=188) or surveillance (Arm B, n=188) after RT
(NTC006653848). Neoadjuvant/adjuvant ADT was mandatory for all the patients. The primary
endpoint was a rising PSA > 2 ng/ml above the nadir PSA value. Intermediate- or high-risk
prostate cancer was defined as T2 with a Gleason score (GS) of 4+3, PSA>10; T2, GS 8-10 any
PSA; or any T3.
The patients were followed for 5 years by assessing PSA levels every 3 months for two years
and every 6 months thereafter.
Outcome measurements and statistical analysis: The study power was 89% to detect a
difference between groups in biochemical disease-free survival (BDFS), and the sample size
calculation accounted for the T2/T3 distribution, where a 12%/15% difference in BDFS was
assumed for the T2/T3 patients.
Results and limitations: All six cycles were completed in 147 (78%) of the patients in arm A.
The median age was 67 years in both treatment groups, and 75% had T3 disease, and 46% had
GS 8-10. The median follow-up was 59 months (range 1 to 111 months). The primary endpoint
was observed for 58 patients in Arm A (docetaxel) and for 57 patients in Arm B (surveillance).
The Kaplan-Meier analysis showed no difference in the BDFS curves (p=0.6) between the
5treatment groups. The 5-year estimated biochemical progression rates were 31% for Arm A and
28% for Arm B. Febrile neutropenia occurred in 16% of the docetaxel patients. No deaths were
related to the docetaxel treatment. There were 43 deaths during the trial, including 20 in Arm
A and 23 in Arm B, of which 9 and 7, respectively, were due to PCa. The Hazard Ratio from
Cox multivariate analysis for PSA progression of Arm A (docetaxel) vs Arm B (surveillance)
was 1.14 (95% CI 0.79 to 1.64, p=0.5).
Conclusions:  Adjuvant  docetaxel  without  prednisone  did  not  improve  BDFS  after  radical
radiotherapy with ADT for intermediate- or high-risk prostate cancer.
Patient summary: We compared six cycles of adjuvant docetaxel given after radical external
radiotherapy plus ADT to surveillance in intermediate- and high-risk localized prostate
cancer. We found no overall benefit in this setting.
6Introduction
Radical prostatectomy or radiotherapy is evidence based treatment options for  intermediate- or
high-risk localized prostate cancer (PCa) (1,2).  However, the risk of biochemical recurrence
after surgery or radiotherapy for high-risk disease is approximately 50% at 5 years (3-5). After
a recurrence with distant metastases, several new treatment options are available today,
including enzalutamide, abiraterone, cabazitaxel, sipuleucil-T, enzalutamide, abiraterone, and
radium-223 (6,7). However, metastatic disease eventually leads to death. Higher stage, higher
Gleason score (GS) and high prostate specific antigen (PSA) levels correlate to cancer specific
and overall survival in long-term follow-ups (5).
In 2004, two randomized trials showed that a docetaxel-based treatment given every third week
prolonged survival in metastatic castrate resistant prostate cancer (mCRPC), and later, a
biweekly dosing of docetaxel was shown to be better tolerated and gave a survival gain in our
study (8-10). In addition, two large prospective randomized trials (CHAARTED and
STAMPEDE) have shown survival gain with docetaxel in metastatic hormone naïve prostate
cancer combined to androgen deprivation therapy (11-13). In early breast cancer, adjuvant
docetaxel-based regimen was accepted as standard of care over ten years ago (14, 15). However,
today using gene profiling, like in the TAILORx trial with hormone receptor positive and Her-
2 negative breast cancer patients, we could avoid adjuvant chemotherapy in many breast cancer
patients (16). The SPCG-group  initiated two prospective open labelled, randomized trials to
evaluate a possible benefit of docetaxel as an adjuvant treatment after local curative treatment
in prostate cancer e.g., SPCG-12 and SPCG-13. In the SPCG-12 trial, the patients were
randomized to receive six cycles of docetaxel without ADT or surveillance after radical
prostatectomy.  However,  docetaxel  was  not  beneficial  in  our  SPCG-12  trial,  as  recently
published by Ahlgren and co-workers (17)
7The aim of this SPCG-13 trial was to evaluate if docetaxel combined with neo/adjuvant
hormonal therapy improved biochemical disease-free survival (BDFS) after a radical
radiotherapy for high- or intermediate-risk PCa patients.
8Patients and methods
The key inclusion criteria in the SPCG trial-13 were the following: men > 18 and ≤75 years of
age; WHO/ECOG performance status 0 – 1; histologically proven adenocarcinoma of the
prostate within 12 months prior to randomization; one of the following: T2 with Gleason 7
(4+3) and PSA >10 ng/ml to < 70 ng/ml or T2 with Gleason 8-10; PSA < 70 ng/ml or any T3
tumours. According to the NCCN guidelines SPCG-13 patients belong to intermediate- or high-
risk group (5). Prior neoadjuvant hormone therapy was mandatory for all the patients, and
adequate haematological, liver and kidney function (less than 1.5 x UNL for creatinine, less
than  1.5  X UNL for  liver  laboratory  values  except  bilirubin  <  UNL)  was  required.  The  key
exclusion criteria were metastatic disease, pathologically or clinically node positive cancer, a
history of previous malignant disease (exceptions were made for basal cell carcinoma and
squamous cell carcinoma of the skin and curatively treated malignant disease, which had been
disease free for the past five years), previous radiotherapy to pelvic region, previous
chemotherapy within five years, systemic corticosteroids within 6 months prior to
randomization, unstable cardiovascular disease within 6 months prior to randomization or
active untreated infectious disease known allergy to Polysorbate 80, other serious illness or
medical condition, symptomatic peripheral neuropathy > CTCAE grade 2 and unable to
cooperate..  All the patients gave written informed consent. The ethics committee approved the
trial. The trial identifier was NTC006653848 (www.clinicaltrial.gov).
The primary endpoint of the trial  was PSA progression. The secondary endpoints were PSA
doubling  time,  Quality  of  Life  (QoL,  measured  by  FACT-P,  18),  safety  (using  Common
Terminology  Criteria  for  Adverse  Events  (CTCAE)  version  3∙0  (http://ctep.cancer.gov),
metastases free survival, and overall survival.
9Between May 2007 and August 2012, a total of 378 patients satisfying the inclusion and
exclusion criteria were randomized after completing RT between the control or six courses of
docetaxel. ADT was continued according the protocol. Permuted block randomization within
each stratum was used. Stratification factors were centre and T stage (T2 vs T3). Randomization
request was recorded on a clinical case report form . It was sent to separate randomization unit
by fax to 4Pharma. Thus, the site personnel did not had access to the randomization list. Most
patients (N=320, 85%) were enrolled from Sweden. The defined endpoint was PSA relapse,
according to the ASTRO-RTOG guidelines (19), with progression of PSA defined >2.0 ng/ml
above  nadir,  with  censoring  at  the  last  PSA measurement,  and  discontinuations  during  PSA
follow-up (including deaths from other causes) censored at the time of death/discontinuation.
PSA measurements were done every three months after finishing RT for two years then every 6
months until PSA progression or end of trial.
Docetaxel 75 mg/m2 i.v. in 60 minutes was given on day one of each 21-day cycle and started
within three months after radiotherapy (Arm A). Premedication with corticosteroids was used.
No continuous prednisone was prescribed during the docetaxel therapy. Arm B; No docetaxel
treatment. Neoadjuvant LH-RH analogue 3 months before RT, during RT and 3 months after
RT (altogether, there were 3 injections every third month or monthly injections, treatment lasted
9 months). Both groups received 3D conformal radiotherapy or intensity modulated
radiotherapy (IMRT) alone or combined to brachytherapy, tumour dose at least 74 Gray.
Statistical calculations
The null hypothesis of ‘no difference in the PSA recurrences experience between the treatment
groups’ was tested against the corresponding nondirectional alternative hypothesis using the
log-rank test. Since the recurrence times were assumed to follow mixing distributions, the
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sample size and the power for the study were estimated through simulation with specific hazard
rates for each of the periods with different recurrence rates.
The calculations were done using software nQuery Advisor 6.0 and with following
assumptions: uniformly distributed inclusion times on the interval [0, 3] years; 70/30 mixture
of subjects with T3/T2 prostate cancer 5-year recurrence rates of 70%/36% for T3/T2 patients
in surveillance group; a 15%/12% difference in BDFS in favour of docetaxel was assumed for
the T3/T2 patients; a two-sided null hypothesis; and a significance level of 5%. With 360
evaluable subjects evenly distributed between the treatment groups, the study had a power of
89% to show the anticipated difference between the treatment groups. The planned number of
patients to be recruited was 378, assuming a 5% non-evaluable inclusion.
The Cox proportional hazards model was used in order to conduct the multivariate analysis of
the prognostic factors. Survival was estimated with Kaplan-Meier method and BDFS between
groups was compared with the log-rank test.
According to the protocol, a separate safety interim analysis was done and published (20).
Results
Study population and randomization
Altogether 378 patients were included to the study from May 2, 2007 to July 24, 2012, 376 pts
were randomized and started the follow-up (Fig 1). Nine patients withdrew consent after
randomization, and 3 patients were had protocol violations. The randomization was successful,
with comparable risk factors in both arms (Table 1). This high- or intermediate-risk cohort was
enrolled with 75% T3 and 47% GS 8-10 (21% GS 9-10), and the median PSA was 14, and thus,
there were 84% high risk patients in both arms (T3 or PSA over 20). Median radiation dose was
78 Gy in both arms.
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Arm A
A total of 180 (96%) of the 188 patients in Arm A received at least one dose of docetaxel, and
147 (78%) of them received all 6 cycles per the protocol. A dose reduction was necessary in 92
(51%) patients, with no difference seen in the outcome (HR 1.15 for patients with dose
reduction, 95% CI 0.69 to 1.93, p=0.6, in exploratory univariate Cox model for PSA
progression in docetaxel treated patients). Neutropenia grade 3-4 was observed in 79 (44%)
patients who received at least one docetaxel infusion. Twenty-nine episodes of febrile
neutropenia were reported (16%). No docetaxel-related deaths were reported. Other SAE´s that
were more common in Arm A were cardiovascular disease and thromboembolism (Table 2).
However, 78% of patients in Arm A received all the six cycles of docetaxel (Table 3).
Analysis of progression
At the five-year follow-up, the rate of progression was declining and we decided to analyze the
primary endpoint as planned in protocol per follow-up time using the 31st Dec 2017 as the data
cut-off although the number of recurrences were not at the expected level. The end-of-study
visit was at 1-104 months from the randomization. At this time-point, of the 375 patients with
a follow-up registered, 58 patients in Arm A and 57 in Arm B had reached the endpoint
(progression of PSA defined >2.0 ng/ml above nadir).  The median time to progression, death
or last follow-up was 60 months in Arm A and 59 in Arm B (61 months for non-progressors in
both groups). The risk of progression over time in the two arms was illustrated by a Kaplan-
Meier analysis showing no difference between treatment groups (Figure 2) (p=0.6, log-rank
test). The 5-year estimated biochemical progression rates were 31% for Arm A and 28% for
Arm B. There were 43 deaths during the trial, including 20 in Arm A (docetaxel) and 23 in Arm
B (surveillance), of which 9 and 7, respectively, were due to prostate cancer. The 5-year
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estimated death rates were 10% for both treatment groups. In the Cox multivariate analysis with
T stage, treatment group and Gleason Score (GS), GS (p=0.001) was a significant predictor of
PSA progression. The Hazard Ratio for Arm A (docetaxel) vs Arm B (surveillance) was 1.14
(95% CI 0.79 to 1.64, p=0.5) indicating that there was no overall benefit of using docetaxel.
The interaction between GS class (GS over 8/ GS 8 or under) and treatment group was close to
significant (p=0.059) and there was a tendency towards treatment benefit in the high-risk
(Gleason 9-10) subgroup (n=80) with HR 0.67 (95% CI 0.34 to 1.30, p=0.2) for PSA
progression in Arm A (docetaxel) vs Arm B (surveillance) (Figure 3).
Discussion
This is the first published randomized trial of an adjuvant docetaxel treatment after radical
radiotherapy compared to surveillance in PCa patients. Our result does not support the use of
docetaxel after radical radiotherapy for intermediate- or high-risk PCa. This study used
neoadjuvant/adjuvant  ADT  combined  with  RT  and  still  no  beneficial  effect  of  docetaxel  in
BDFS was observed. A recent publication of RTOG 0521 showed a significant overall survival
gain with docetaxel (21). Also improved disease-free survival and reduction in the rate of
distant metastasis was observed. Their study included more advanced patients, e.g., locally
advanced T4 tumors, and with PSA values up to 150 vs 70 in our study. They had 53% with
Gleason score 9-10 and 31% GS 8 (altogether 84% GS 8-10), while only 46% of our patients
had GS 8-10. Thus RTOG 0521 patients had more advanced disease (Table 5). However, in our
study the interaction between treatment group and Gleason class was almost significant
(p=0.059), and the patients in high risk (GS 9-10) had tendency towards benefit (HR 0.67, 95%
CI 0.34 to 1.30, p=0.2) from adjuvant docetaxel. RTOG 0521 used also prednisone with
docetaxel. We did not use prednisone either in SPCG-12 or SPCG-13 trial in order to avoid the
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known side-effects of prednisone. The practice to use it with docetaxel comes from the trials of
advanced PCa, where cortisone is also used to palliate symptoms. Thus, it was combined to
mitoxantrone, which was the comparator to docetaxel in the early trials of mCRPC  like in TAX
327. In addition, our treatment protocol with docetaxel and ADT was different from the
sequential treatment protocols, which are used in adjuvant studies in breast cancer (14,15), were
docetaxel was given before hormonal treatment.
In several studies, combining ADT with RT has been beneficial, and included in RT guidelines
of high- and intermediate-risk PCa (5, 22). We chose a shorter than three years duration of the
LH-RH-analogue to avoid permanent castration in these elderly men and still their BDFS and
overall survival were very good. Also in the recently published phase III PCa trial the shorter
duration of ADT was used after radiotherapy (22). However, long ADT with radiotherapy
remains the standard of care.
In an adjuvant study after radiotherapy in high-risk PCa patients with long follow-up and
survival as an endpoint (RTOG 9902), no difference was seen in either biochemical failure,
distant metastasis free survival or overall survival after a median follow-up of 9.4 years (23).
This study used a probably less effective non-taxane triple chemotherapy in combination with
ADT after RT. In addition, RTOG 9902 was early closed due to the toxicity of chemotherapy
and slow patient  accrual.   In  the  GETUG 12 trial,  docetaxel  and  estramustine  phosphate,  in
combination with ADT, were compared with ADT alone after curative treatment for high-risk
disease and most of them after radiation therapy (24). A significant difference in time to
biochemical recurrence was found in favor of the combination therapy. The primary treatment
was radiotherapy in combination with ADT, and ADT was given for 3 years, and the
progression was defined by PSA >2.0 ng/ml above nadir as in our study. The difference in the
outcome in the GETUG 12 study was seen in patients with a GS≤7, while no effect was seen in
the GS=8 or higher patients. In both the RTOG 9902 and GETUG 12 studies, the primary
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endpoint was biochemical progression, and no conclusion was drawn about metastasis-free or
cancer-specific survival (23,24). Updated results of GETUG-12 were presented in ESMO 2018
(25). According to them four cycles of docetaxel-based chemotherapy reduced risk of clinical
relapse or death in this long-term follow-up (12 years).  In the recently published STAMPEDE
trial, there was no survival benefit from docetaxel combined with ADT compared with ADT
alone for patients with locally advanced disease without proven metastasis at randomization,
but  a  positive  effect  on  PSA  was  observed  (12).  Both  RTOG  trials  had  also  much  more
aggressive tumors (see Table 5, GS distribution) than in our study explaining partly the
difference  in  the  outcome.   Tosco  et  al.  published  recently  systematic  review of  therapeutic
combinations with local treatments for high risk localized prostate cancer (26). They identified
altogether 77 prospective trials. Multiple of them showed benefit of combining ADT with
EBRT compared to EBRT alone and docetaxel showed to increase relapse free survival in
GETUG-12, RTOG 0521 and nonmetastatic group in STAMPEDE with EBRT plus ADT and
according to the recent results of RTOG 0521 improved overall survival was observed.
However, all these trials like ours should have longer follow-up time.
In a recent meta-analysis of the results from clinical trials on the use of docetaxel plus ADT in
hormone naive nonmetastatic locally advanced PCa, the gain in failure-free survival was highly
significant (8%) (27) However, the reduction in survival was four percent, which was not
significant. In the SPCG-12 radical prostatectomy trial, no ADT and no daily prednisone were
used, and likewise as in our study there was no benefit of six cycles of docetaxel. Similar
findings were observed in the TAX 3501 radical prostatectomy study for the arm with the
sequential docetaxel and hormonal treatment, but the number of patients and events was very
low (28). Thus, it seems that the beneficial effect of docetaxel in early PCa is not dependent on
the docetaxel ADT interaction. New therapeutic approaches and molecular profiling as in
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TAILORx trial (16) should be studied, especially in the neoadjuvant situation before
prostatectomy (29) allowing response evaluation more quickly.
The toxicity profile of docetaxel was in line with the previous publications (12-15,17) and no
toxic deaths occurred. Even 78% of the patients received all six cycles of docetaxel. However,
more effort should be done to avoid toxicity in this elderly patient population.
The limitations of our study include having a heterogeneous risk profile in our study population
and that the primary endpoint is BDFS and not survival. However, the inclusion criteria were
designed  based  on  a  50%  risk  of  relapse  by  nomograms.  The  trial  might  have  been
underpowered to detect subgroup differences. There were far fewer relapses than expected,
lowering the planned statistical power of the study, even though most of our patients belonged
to the high-risk group, and we will continue the follow-up of our patients.
In the main analysis for biochemical progression the confidence interval of HR (Docetaxel vs
Surveillance) spreads from 0.79 to 1.64 indicating that there is no clear difference in favor of
either treatment arm. The lower limit of 0.79 do not indicate signs of considerable overall
benefit of docetaxel over surveillance based on this study. In conclusion, based on our current
results there is no evidence that adjuvant docetaxel with ADT after radiotherapy would provide
benefit for intermediate- or high-risk prostate cancer patients in general clinical practice.
However, whether docetaxel could improve outcomes in high-risk local prostate cancer cannot
be ruled-out by this trial and based on the results of RTOG 0521 trial, adjuvant docetaxel should
be discussed with patients as a treatment options for high-risk prostate cancer.
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Table 1. Baseline characteristics in Arm A and Arm B.
Factor Adjuvant Docetaxel
(Arm A, n=188)
Surveillance
(Arm B, n=188)
Age median (IQR) 67 (63-70) 67 (63-71)
PSA median before RT (ng/ml, IQR) 14.6 (8.2-29.0) 14.0 (7.0-26.0)
PSA median after RT (ng/ml, IQR) 0.50 (0.15-2.80) 0.57 (0.12-1.75)
T-stage T2 / T3 (%) 26 / 74 24 / 76
Gleason ≤7 / 8/9-10 (%) 56 / 26 /18 51 / 25 / 24
WHO status 0 / 1 (%) 93 / 7 95 / 5
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Table 2. Reported number of serious adverse events (SAE) in Arm A and Arm B. Some
patients several SAE´s.
Type of SAE Arm A
(docetaxel)
N=188
Arm B
(surveillance)
N=188
Total
Febrile neutropenia 43 0 43
Infection no neutropenia 12 2 14
Toxic/allergic reaction 2 0 2
Prostate cancer (death) 6 3 9
Other cancer 9 5 14
Other surgery 7 17 24
Cardiovascular disease 16 8 24
Chest pain (observation) 4 1 5
Thromboembolism 5 1 6
Benign bowel disease 5 1 6
Gastric ulcer 2 0 2
Other 5 3 8
Total 116 41 157
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Table 3. Docetaxel treatment delivered at each cycle
No. cycles Frequency Percent (%)
Cumulative
Percent (%)
0 8 4 4
1 12 6 11
2 6 3 14
3 5 3 16
4 5 3 19
5 5 3 23
6 147 78 100
Total 188 100
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Table 4. Uni- and multivariate Cox analysis of Hazard Ratio to have progression to end-point
PSA≥2.0 ng/ml for prognostic factors and treatment Arm.
 Prognostic factor
Univariate analysis n=375 p-value    HR
(95% Ci)
Multivariate analysis n=375
p-value    HR (95% Ci)
T-stage T2 vs. T3 1.0 0.99 (0.65-1.53) 0.18  0.73 (0.46-1.15)
Gleason sum (linear effect of 1 unit*) <0.001 1.47 (1.22-1.78) 0.001  1.52 (1.22-1.88)
Arm A vs. Arm B 0.6 1.09 (0.76-1.58) 0.5  1.14 (0.79-1.64)
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Table 5. Summary of adjuvant trials in prostate cancer using docetaxel combined to ADT and
radical radiotherapy.
CT=chemotherapy, D=docetaxel, E=Estramustine, Eto=etoposide, P= paclitaxel, RFS=
recurrence free survival, OS= overall survival, BDFS= biochemical disease-free survival
Trial T PSA (ng/ml) GS ADT CT Results
GETUG-12 T 1-2 23%
T 3-4 67%
N+ 29%
>20, 59% GS > 8, 42% 36 months DE x 4 12 yr. RFS
49% vs 36%
p=0.01
RTOG 9902 T 1-2 66%
T 3-4 34%
23 median GS > 8, 68% 28 months E+Eto+P
x 4
10 yr. OS
65% vs 63%,
P=0.8
RTOG 0521 T 1-2 73%
T 3-4 27%
15 median GS 8-10, 84% 28 months D x 6 4 yr. OS 86%
vs 81%,
p=0.03
SPCG-13 T 2 25%
T 3 75%
14 median GS 8-10, 46% 9 months D x 6 5 yr. BDFS
69% vs 70%,
p=0.6
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Fig. 1. Trial profile for SPCG13: Arm A adjuvant, Arm B surveillance only.
376 patients
randomised
Arm A: 188 pts
assigned to
docetaxel
180 pts  received
≥1dose of
docetaxel
177 pts
followed ≥3
months for
progression
171 pts
completed
follow-up
3 pts withdrew
consent
4 pts lost to follow-up
1 protocol violation
1 withdrew consent
4 pts withdrew consent
2 pts protocol violation
1 with no follow-up
1 lost to follow-up
Arm B: 188 pts
assigned to
surveillance
188 followed
≥3 months for
progression
186 completed
follow-up
1 lost to follow-
up
1 withdrew
consent
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Fig 2.  Kaplan-Meier curves of survival free of progression (PSA > 2.0ng/ml) by intent to
treat (p=0.6).
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Fig. 3. Forest plot of Hazard Ratio for biochemical progression (PSA > 2.0ng/ml) in
subgroups for the variables used in multivariate analysis.
